Floatz logo

JAB 3068

Other Metastatic Solid Tumors

Jacobio Pharmaceuticals Co., Ltd.Small moleculePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Other Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Eloxatin
Ruijin Hospital
Phase 4BBB
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

JAB 3068 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
head and neck cancerDormant
CCC
Indicative ·
55 / 100
View asset →
esophageal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →